Safety and Tolerability of NTRX-07 in Healthy Volunteers

NTRX 07-C101: A Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Single Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers

Randomized, placebo-controlled, modified parallel-design single ascending dose (SAD) in adult healthy volunteers (HVs).

Study Overview

• Status: Completed
• Conditions: Pain, Neuropathic
• Intervention / Treatment: Drug: NTRX-07-SDD

Detailed Description

Study NTRX-07-C101 will be conducted with a modified parallel design, incorporating sentinel subjects and a staggered-dosing-days approach.

Up to 6 cohorts, A-F, are planned for a total of 48 completing subjects. Each dose cohort will be randomized with 6 subjects receiving active drug and 2 placebo.

• Study Type: Interventional
• Enrollment (Actual): 48
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Tustin, California, United States, 92780
      • Orange County Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• • Written, informed consent.

  • Adult healthy male or females, ages 18-60 years, inclusive, who are surgically sterilized (including hysterectomy and/or bilateral oophorectomy but not tubal ligation) or naturally postmenopausal (2 without menses and documented blood follicle-stimulating hormone ≥40 MIU/mL).

years

• Good health as determined by medical history, physical examination, vital signs, ECG, and clinical laboratory measurements.
• Clinical laboratories within normal limits at screening (including blood glucose).
• Body mass index (BMI) of 18-35 kg/m 2 inclusive with body weight

>50 kg.

• Able to comply with the study regimen.

Exclusion Criteria:

• Any acute or chronic illness.

  • Pregnant or lactating females.
  • Positive serology for human immunodeficiency virus (HIV), hepatitis B virus (HBV) (if not vaccinated) or hepatitis C virus (HCV).
  • Any known or suspected allergies to the study drug or its constituents.
  • Inadequate venous access to allow collection of blood samples.
  • History of drug or alcohol abuse, consumption of alcohol within 48 hours prior to treatment assignment, or a positive test for alcohol or drugs with a high potential for abuse prior to treatment assignment and readmission to the Clinical Research Unit (CRU).
  • Subjects with history of (within the previous 12 months) or current use of marijuana or positive urine drug screen for cannabinoids at screening or prior to the first dose.
  • History of seizures or current existing seizure disorder. High risk for seizure disorders due to underlying medical condition and/or head trauma.
  • Is a smoker of more than 10 cigarettes or 3 cigars or 3 pipes per day, and is unable to refrain from smoking while confined to the CRU.
  • Calculated creatinine clearance (using Cockroft and Gault formula) <80 mL/min.
  • Resting 12-lead ECG showing QTcB interval >450 msec or any other clinically significant abnormality in the opinion of the investigator/ sponsor.
  • Blood donation, participation in a multiple blood draws clinical study 30 days prior (>120 mL)
  • Major trauma or surgery with or without blood loss within 90 days prior to treatment assignment.
  • Use of any experimental or investigational drugs within 30 days prior to treatment assignment.
  • Use of any prescription or nonprescription drugs, vitamins, or dietary supplements within 14 days prior to treatment assignment, or expected use during trial enrollment.
  • Any current condition, that in either the Investigator's or sponsor's opinion would represent an unacceptable safety risk while participating in this study or interfere with trial participation or evaluation of results.
  • Severe mental incapacity, unwillingness, language barrier, serious behavioral issues, evidence of substance abuse, or any other situation, which would preclude an understanding of, and adherence to study procedures

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: NTRX-07-SDD; NTRX-07-SDD at 0.3-8mg/kg; single dose	Drug: NTRX-07-SDD; NTRX-07-SDD for oral administration; Other Names: MDA7
Placebo Comparator: Control; Placebo control	Drug: NTRX-07-SDD; NTRX-07-SDD for oral administration; Other Names: MDA7

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of subjects with treatment emergent adverse events of NTRX-07	Reported Treatment related Adverse Events	Seven days
Number of subjects with Treatment related subjective effects of NTRX-07	Reported Treatment related subjective effects Events	Seven days
Plasma levels of NTRX-07	Plasma levels of NTRX-07	24 hours

Collaborators and Investigators

• Sponsor: NeuroTherapia, Inc.
• Collaborators: Integrium; Orange County Research Center
• Investigators: Study Director: Joseph Foss, MD, NeuroTherapia, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): October 10, 2019
• Primary Completion (Actual): May 15, 2020
• Study Completion (Actual): June 30, 2020

Study Registration Dates

• First Submitted: April 13, 2020
• First Submitted That Met QC Criteria: May 4, 2020
• First Posted (Actual): May 5, 2020

Study Record Updates

• Last Update Posted (Actual): November 8, 2023
• Last Update Submitted That Met QC Criteria: November 7, 2023
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Pain; Neurologic Manifestations; Neuromuscular Diseases; Peripheral Nervous System Diseases; Neuralgia
• Other Study ID Numbers: NTRX-07-C101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No